Julian Joon Ip Wong

Dr. Julian Joon Ip Wong

Department of Psychological Medicine, Universiti Malaya, Kuala Lumpur, Malaysia
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in Medicina
Verified
Journal Article
Open access
PDF file
MZMUHAMMAD AKMAL ZAKARIA
MUHAMMAD AKMAL ZAKARIA
OKOng Hui Koh
Ong Hui Koh
HSHEMA SUBRAMANIAM
HEMA SUBRAMANIAM
MRMaziah Mat Rosly
Maziah Mat Rosly
JGJesjeet Singh Gill
Jesjeet Singh Gill
BFBenedict Francis
Benedict Francis
Background and Objectives: Depression is a leading cause of disability globally, with treatment challenges including limited access, stigma, and poor adherence. Gamification, which applies game elements such as points, levels, and storytelling into non-game contexts, offers a promising strategy to enhance engagement and augment traditional treatments. Our research is the first study designed to explore the implementation of gamification within the Malaysian context. The objective was to explore the feasibility of implementation of gamification as an adjunctive treatment for adults with depression. Materials and Methods: Focus group discussions were held with five mental health professionals and ten patients diagnosed with moderate depression. The qualitative component assessed perceptions of gamified interventions, while quantitative measures evaluated participants’ depressive and anxiety symptomatology. Results: Three key themes were identified: (1) understanding of gamification as a treatment option, (2) factors influencing its acceptance, and (3) characteristics of a practical and feasible intervention. Clinicians saw potential in gamification to boost motivation, support psychoeducation, and encourage self-paced learning, but they expressed concerns about possible addiction, stigma, and the complexity of gameplay for some patients. Patients spoke of gaming as a source of comfort, escapism, and social connection. Acceptance was shaped by engaging storylines, intuitive design, balanced difficulty, therapist guidance, and clear safety measures. Both groups agreed that gamification should be used in conjunction with standard treatments, be culturally sensitive, and be presented as a meaningful therapeutic approach rather than merely as entertainment. Conclusions: Gamification emerges as an acceptable and feasible supplementary approach for managing depression in Malaysia. Its success depends on culturally sensitive design, robust clinical oversight, and seamless integration with existing care pathways. Future studies should investigate long-term outcomes and establish guidelines for the safe and effective implementation of this approach. We recommend targeted investment into culturally adapted gamified tools, including training, policy development, and collaboration with key stakeholders to realistically implement gamification as a mental health intervention in Malaysia.

16 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
TRTHARISHINI RAMACHANDRAN
THARISHINI RAMACHANDRAN
NGNg Chong Guan
Ng Chong Guan
Julian Joon Ip WongJulian Joon Ip Wong
Julian Joon Ip Wong
AAAida Syarinaz Binti Ahmad Adlan
Aida Syarinaz Binti Ahmad Adlan
Background: A significant percentage of patients with major depressive disorder (MDD) fail to achieve remission with antidepressant monotherapy and frequently experience residual mood and cognitive symptoms that impair their functional recovery. Thus, an augmentation with vortioxetine, a multimodal antidepressant with reported cognitive benefits, might be a useful strategy for such patients. Methods: We conducted a 12-week naturalistic, prospective observational study in a Malaysian university hospital. 40 adults with MDD and inadequate response to at least eight weeks of antidepressant therapy received either adjunctive vortioxetine or optimization of their existing antidepressant as part of treatment-as-usual care. Depressive symptoms were assessed using the Montgomery–Åsberg Depression Rating Scale (MADRS), cognitive symptoms using the Perceived Deficits Questionnaire-5 (PDQ-D5), and global improvement using the Clinical Global Impressions–Improvement (CGI-I) scale. Results: Both groups demonstrated significant improvements in MADRS and PDQ-D5 scores over 12 weeks (p < 0.001). Remission rates at Week 12 were high in both groups (93.8% adjunctive vortioxetine vs 86.7% control). While between-group differences were not statistically significant, patients receiving vortioxetine showed earlier improvement in several core depressive symptoms, including apparent sadness, suicidal ideation, and appetite disturbance. Greater clinician-rated global improvement was observed in the vortioxetine group at Week 12 (87.5% vs 40.0%, p < 0.001). Conclusions: In this outpatient clinical setting, adjunctive vortioxetine was associated with earlier improvement of core depressive symptoms and greater global clinical improvement compared with optimization of existing antidepressant therapy. Collectively, these findings suggest adjunctive vortioxetine as a clinically relevant option for patients with MDD who show an inadequate response to antidepressant monotherapy.

10 September 2025 in Sleep Science and Practice
Verified
Journal Article
Open access
PDF file
Julian Joon Ip WongJulian Joon Ip Wong
Julian Joon Ip Wong
Chronic use of benzodiazepines and Z‑drugs for insomnia carries risk of dependence, tolerance, and withdrawal. Dual orexin receptor antagonists (DORAs) such as lemborexant offer a non‑GABAergic alternative to these agents as an alternative pharmacological agent of treatment for insomnia. To describe two clinical cases illustrating successful cross‑tapering from high‑dose benzodiazepines or zolpidem to lemborexant. Patient 1 (inpatient): cross‑tapered from ~ 100 mg/day diazepam to lemborexant 10 mg/night over two weeks with stable sleep quality and no withdrawal. Patient 2 (outpatient): cross‑tapered from zolpidem 40 mg/night to lemborexant 10 mg/night over five weeks, with sustained sleep and eventual dose reduction to 5 mg/night. Lemborexant demonstrated clinical utility in facilitating transition from conventional hypnotic dependence, maintaining subjective sleep quality, and minimizing adverse effects. These findings support its role aligned with recent consensus guidelines on use of hypnotics in management of insomnia.

6 November 2026 in Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
JPJia Yang Poi
Jia Yang Poi
CNChong Guan Ng
Chong Guan Ng
Julian Joon Ip WongJulian Joon Ip Wong
Julian Joon Ip Wong
DTDavid Ming Gui Tan
David Ming Gui Tan
Background: This study evaluated the effects of adjunctive brexpiprazole in adult patients with Major Depressive Disorder (MDD) who experienced an inadequate response to antidepressant therapy. Methods: This 12-week, multicentre, naturalistic, prospective observational study enrolled 60 adults with MDD and an inadequate response to at least two antidepressant treatments. Depressive symptoms, anxiety, clinician-rated illness severity and improvement, functioning, and quality of life were assessed using the Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), Clinical Global Impressions—Severity (CGI-S) and —Improvement (CGI-I), Sheehan Disability Scale (SDS), and World Health Organization Quality of Life—Brief Version (WHOQOL-BREF). GAD-7 was assessed only at baseline and week 12. Inferential analyses used complete observations without imputation. Results: Fifty participants (83.3%) completed week 12 and contributed to the principal symptom analyses. Mean PHQ-9 scores decreased from 16.68 ± 5.64 to 11.50 ± 7.30, and GAD-7 scores from 13.32 ± 4.98 to 9.80 ± 5.63 (both p < 0.001). At week 12, PHQ-9 response and remission rates among these 50 participants were 38.0% and 22.0%; corresponding GAD-7 rates were 34.0% and 14.0%. Mean CGI-S decreased from 5.00 ± 1.16 to 3.52 ± 1.79 (p < 0.001); mean week-12 CGI-I was 2.44 ± 1.22. In 43 participants with all three SDS domains recorded at both visits, mean total SDS decreased from 16.79 ± 7.26 to 11.74 ± 8.65 (p < 0.001). Physical, psychological, and social relationship WHOQOL-BREF domains improved, whereas the overall quality-of-life item did not change significantly. Conclusions: In clinical practice, adjunctive brexpiprazole was associated with early improvement in depressive symptoms and improvements in anxiety symptoms, illness severity, psychosocial functioning, and quality-of-life domains.

20 May 2026 in Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
TRTHARISHINI RAMACHANDRAN
THARISHINI RAMACHANDRAN
NGNg Chong Guan
Ng Chong Guan
Julian Joon Ip WongJulian Joon Ip Wong
Julian Joon Ip Wong
AAAida Syarinaz Binti Ahmad Adlan
Aida Syarinaz Binti Ahmad Adlan
Background: A significant percentage of patients with major depressive disorder (MDD) fail to achieve remission with antidepressant monotherapy and frequently experience residual mood and cognitive symptoms that impair their functional recovery. Thus, an augmentation with vortioxetine, a multimodal antidepressant with reported cognitive benefits, might be a useful strategy for such patients. Methods: We conducted a 12-week naturalistic, prospective observational study in a Malaysian university hospital; 40 adults with MDD and inadequate response to at least eight weeks of antidepressant therapy received either adjunctive vortioxetine or optimization of their existing antidepressant as part of treatment-as-usual care. Depressive symptoms were assessed using the Montgomery–Åsberg Depression Rating Scale (MADRS), cognitive symptoms using the Perceived Deficits Questionnaire-5 (PDQ-D5), and global improvement using the Clinical Global Impressions—Improvement (CGI-I) scale. Results: Both groups demonstrated significant improvements in MADRS and PDQ-D5 scores over 12 weeks (p < 0.001). Remission rates at Week 12 were high in both groups (93.8% adjunctive vortioxetine vs. 86.7% control). Both groups demonstrated significant improvements in depressive and cognitive symptoms over 12 weeks. Although between-group differences were not statistically significant, descriptive trends toward earlier symptomatic improvement were observed in the adjunctive vortioxetine group in several core depressive symptoms, including apparent sadness, suicidal ideation, and appetite disturbance. Greater clinician-rated global improvement was observed in the vortioxetine group at Week 12 (87.5% vs. 40.0%, p < 0.001). Conclusions: In this outpatient clinical setting, adjunctive vortioxetine was associated with earlier improvement of core depressive symptoms and greater global clinical improvement compared with optimization of existing antidepressant therapy. Collectively, these findings suggest adjunctive vortioxetine as a clinically relevant option for patients with MDD who show an inadequate response to antidepressant monotherapy; however, findings are exploratory and not causal, and thus larger RCTs are needed for affirmation.

23 September 2020 in medRxiv
Verified
Preprint
Open access
PDF file
BFBenedict Francis
Benedict Francis
YNYit Ng
Yit Ng
Julian Joon Ip WongJulian Joon Ip Wong
Julian Joon Ip Wong
LTLing Shiau Thin
Ling Shiau Thin
JGJesjeet Singh Gill
Jesjeet Singh Gill
Ahmad Hatim SulaimanAhmad Hatim Sulaiman
Ahmad Hatim Sulaiman
Background: Relapse prevention strategies are important as part of optimal patient care. As such, maintenance electroconvulsive therapy (mECT) is an important treatment modality to keep patients in remission longer. However, the practice of mECT in Malaysia, specifically and Asia generally, is still scarce. Aims: Our study aimed to explore the characteristics of patients receiving maintenance ECT (mECT) and further investigate whether this treatment modality reduces re-admission days in patients with severe mental illness. Methods: A retrospective chart review study design was employed. The medical records of 22 patients followed up at University Malaya Medical Centre, Malaysia were analysed with regards to the outcome measures, which was days of re-admission post mECT, Potential confounders were controlled for via stratification analysis. Results: There was a significant reduction in re-admission days post mECT (p<0.001, r:0.85) across all the variables analysed. The variable with the biggest effect size were patients younger than 60 years old (p:0.01, r:0.70), followed by medication with polypharmacy (p:0.002, r: 0.65). The magnitude of reduction in re-admissions was greater in the schizophrenia spectrum group compared to the affective disorders group (r: 0.64 vs. 0.57). Conclusion: Our study provides data regarding the efficacy of mECT in significantly reducing days of re-admission in patients with treatment resistant schizophrenia spectrum illness and affective disorders. As widespread usage of mECT is still lacking in Asia, our results is encouraging for more practitioners to prescribe mECT for their patients in order to reduce rates of hospital re-admission.